The extreme dilution (~206% to pro forma shares) and the ~10.7% discount to the prior close will likely pressure the stock at the open. The massive overhang of 25.8M pre-funded warrants at $0.0001/share adds further downside risk. Traders should watch for the stock to trade toward or below the $26 offering price as the market absorbs the new supply. The 60-day lock-up provides some near-term stability, but the pre-funded warrant overhang is not locked up.
Price Chart
Executive Summary
Yarrow Bioscience is pricing a $150M follow-on offering of 5,769,231 shares at $26.00/share, a ~10.7% discount to the prior close of $29.11. The offering represents a massive ~206% dilution to the pro forma share count of 2.8M shares outstanding. Net proceeds of ~$140.7M will extend the cash runway into 2030 to fund Phase 2b GD and TED studies. The filing also discloses ~$108.8M in cash as of Aug 31, 2026, up from $18.7M at June 30, 2026, and a massive overhang of 25.8M pre-funded warrants at $0.0001/share that could further dilute if exercised. The deep discount, extreme dilution, and pre-funded warrant overhang make this a clear bearish event for existing shareholders.
Key Facts
- Offering 5,769,231 shares at $26.00/share, a ~10.7% discount to the $29.11 prior close
- Total offering size of ~$150M; net proceeds of ~$140.7M to Yarrow
- Pro forma shares outstanding post-offering: 8,572,309 (or 9,437,693 if underwriters' option exercised in full), representing ~206% dilution from the 2,803,078 pro forma shares outstanding as of June 30, 2026
- Underwriters have a 30-day option to purchase an additional 865,384 shares
- Estimated cash and cash equivalents of ~$108.8M as of Aug 31, 2026, up from $18.7M as of June 30, 2026
- 25,781,240 pre-funded warrants outstanding at $0.0001/share as of June 30, 2026, representing massive additional potential dilution
- Company expects net proceeds to fund operations into 2030, including Phase 2b GD trial and preparatory work for next TED study
- Lock-up agreements for officers, directors, and certain stockholders for 60 days post-offering
Financial Impact
~$150M gross / ~$140.7M net proceeds raised via ~206% dilution at a ~10.7% discount to market price
Risk Factors
- Extreme dilution of ~206% to existing shareholders
- Massive overhang of 25.8M pre-funded warrants at $0.0001/share that could be exercised at any time
- Clinical-stage biotech with no approved products or revenue — high execution risk on YB-101 trials
- Company will need substantial additional capital beyond this raise to reach regulatory approval and commercialization
- Potential for further equity offerings given the $50M ATM facility with TD Securities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-107112 |
| Document: 0001104659-26-107112-index-headers.html | 0001104659-26-107112 |
| Document: 0001104659-26-107112-index.html | 0001104659-26-107112 |
| Document: 0001104659-26-107112.txt | 0001104659-26-107112 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 17, 2026 5w ago | SC 13G | $29.29 $18.31 | ▼ −37.49% | ▼ −37.69% | $20.00 (−31.72%) |
Sep 11, 2026 6w ago | 424B5 | $26.26 $19.82 | ▲ +24.52% | ▲ +26.79% | $20.00 (+23.84%) |
Aug 20, 2026 9w ago | EFFECT | $38.20 $29.29 | ▲ +23.32% | ▲ +23.32% | $20.00 (+47.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers